ALK inhibitors 

(e.g., crizotinib, ceritinib, brigantinib, alectinib)

Cardio-oncological evaluation*

before cancer treatment begins

Cardio-oncological evaluation*

every 3 months for 1 year, then every 6 months during cancer treatment

* A cardio-oncological evaluation will systematically include at least one visit with blood pressure, blood glucose, lipid profile, GFR calculation, ECG and trans-thoracic echocardiography (TTE). Measurements of global longitudinal strain and 3D LVEF (if feasible) are recommended with the same machine.

Logo final.png

Centre Méditerranéen Hospitalo-Universitaire de Cardio-Oncologie

​Hôpital Nord, chemin des Bourrely, 13015 Marseille, France

Aix-Marseille Université

Nous contacter

  • Facebook Social Icône


© 2020 by Franck Thuny